Biofrontera Inc

NASDAQ:BFRI

1.69

+0.02 (+1.20%)

7:41:02 PM EDT: $1.71 +0.02 (+1.18%)

Market Cap (Intraday)	8.60M
Current PE	N/A
Forward PE	N/A
2yr Forward PE	N/A

See more stats

Estimates Current Quarter

Revenue	$10.86 Million
Adjusted EPS	-$1.17

See more estimates

10-Day MA	$1.79
50-Day MA	$1.31
200-Day MA	$4.90

See more pivots

Biofrontera Inc Stock, NASDAQ:BFRI

120 Presidnetial Way, Suite 330, Woburn, Massachusetts 01801

United States of America

Phone: +1.781.245.1325

Number of Employees: 85

http://www.biofrontera-us.com

Description

Biofrontera, Inc. is a biopharmaceutical company, which engages in the commercialization of pharmaceutical products. It specializes in the treatment of dermatological conditions, caused primarily by exposure to sunlight that results in sun damage to the skin. The company is focused on the treatment of actinic keratosis and markets a topical antibiotic for treatment of impetigo. Its products include Ameluz and Xepi, its two prescription drugs, and BF-RhodoLED, a lamp used with Ameluz, for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. The company was founded on March 3, 2015 and is headquartered in Woburn, MA.